Disease-free survival variables | Â | Univariable analysis | Multivariable analysis | ||||
---|---|---|---|---|---|---|---|
 | HR | (95% CI) | p Value | HR | (95% CI) | p Value | |
 Tumor size | < 4 cm | 1 | 0.6 | 1 | 0.2 | ||
≥ 4 cm | 1.35 | (0.43 to 4.19) | 0.43 | (0.09 to 1.94) | |||
 Nuclear grade | 1/2 | 1 | 0.9 | 1 | 0.06 | ||
3 | 1 | (0.28 to 3.56) | 0.15 | (0.02 to 1.13) | |||
 ER | + | 1 | 0.03 | 1 | 0.03 | ||
– | 3.72 | (1.12 to 12.3) | 7.53 | (1.17 to 48.33) | |||
 Nodal involvement | – | 1 | 0.09 | 1 | 0.4 | ||
+ | 5.75 | (0.74 to 44.2) | 2.25 | (0.25 to 19.9) | |||
 FMISO-TBR | < 1.48 | 1 | 0.002 | 1 | 0.005 | ||
≥ 1.48 | 5.72 | (1.83 to 17.82) | 11.35 | (2.07 to 62.23) | |||
 Chemotherapy |  | 1 | 0.9 | N/A | |||
+ | 368,675.3 | (5.3E-168 to 25.4E + 177) | |||||
Overall survival variables | Â | Univariable analysis | Multivariable analysis | ||||
 | HR | (95% CI) | p Value | HR | (95% CI) | p Value | |
 Tumor size | < 4 cm | 1 | 0.6 | 1 | 0.7 | ||
≥ 4 cm | 1.45 | (0.29 to 7.15) | 0.71 | (0.1 to 4.71) | |||
 Nuclear grade | 1/2 | 1 | 0.9 | 1 | 0.2 | ||
3 | 1.09 | (1.18 to 6.57) | 0.21 | (0.01 to 2.82) | |||
 ER | + | 1 | 0.2 | 1 | 0.1 | ||
– | 3.03 | (0.55 to 16.5) | 10.24 | (0.57 to 181.96) | |||
 Nodal involvement | – | 1 | 0.9 | 1 | 0.9 | ||
+ | 411,595.95 | (9.7E-202 to 1.74E + 210) | 141,679.29 | (7.17E-223 to 27.97E + 231) | |||
 FMISO-TBR | < 1.48 | 1 | 0.06 | 1 | 0.1 | ||
≥ 1.48 | 4.43 | (0.88 to 22.17) | 7.59 | (0.63 to 90.68) | |||
 Chemotherapy |  | 1 | 0.9 | N/A | |||
+ | 122,960.7 | (6.7E-167 to 222.6E + 174) |